Drugs / nasea
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01703351 Comparator | Oct 2012 → Nov 2015 | lung neoplasm | Yonsei University | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | nasea | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01703351 ↗ |
| Route | Intravenous | “IV PCA (Fentanyl 500mcg + acupan 160mg + nasea 0.6mg, 5cc/hr for 60 hours after operation, 0.5cc bolus if patients feel breakthrough pain)” NCT01703351 ↗ |